Post-Hoc: The world's biggest drugmaker get more secretive

Eli Lilly has stopped disclosing its early-stage pipeline and most deal values as it grows larger. An analysis of why the drugmaker's rising secrecy erodes trust.

Raccontata daendpoints.news